Espinoza-Sánchez Nancy Adriana, Győrffy Balázs, Fuentes-Pananá Ezequiel M, Götte Martin
Unidad de Investigación en Virología y Cáncer, Hospital Infantil de México Federico Gómez, C.P. 06720, Ciudad de México, México.
MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, and Semmelweis University 2nd Dept. of Pediatrics, Budapest, Hungary.
J Cancer. 2019 Aug 28;10(21):5191-5211. doi: 10.7150/jca.34302. eCollection 2019.
Inflammation is a well-known driver of carcinogenesis and cancer progression, often attributed to the tumor microenvironment. However, tumor cells themselves are capable of secreting a variety of inflammatory molecules, leading to the activation of specific signaling pathways that promote tumor progression. The NF-κB signaling pathway is one of the most important connections between inflammation and tumorigenesis. NF-κB is a superfamily of transcription factors that plays an important role in several types of hematological and solid tumors, including breast cancer. However, the role of the NF-κB pathway in the survival of breast cancer patients is poorly studied. In this study, we analyzed and related the expression of both canonical and alternative NF-κB pathways and selected target genes with the relapse-free and overall survival of breast cancer patients. We used the public database Kaplan-Meier plotter (KMplot) which includes gene expression data and survival information of 3951 breast cancer patients. We found that the expression of was associated with poor relapse-free survival in patients with ER-positive tumors. Moreover, the expression of and was associated with poor relapse-free and overall survival. In contrast, expression of , and from the canonical pathway, and and from the alternative pathway correlated with better relapse-free survival also when the patients were classified by their hormonal and nodal status. Our study suggests that the expression of genes of the canonical and alternative NF-κB pathways is ultimately critical for tumor persistence. Understanding the communication between both pathways would help to find better therapeutic and prophylactic targets to prevent breast cancer progression and relapse.
炎症是一种众所周知的致癌和癌症进展驱动因素,通常归因于肿瘤微环境。然而,肿瘤细胞本身能够分泌多种炎症分子,导致促进肿瘤进展的特定信号通路激活。NF-κB信号通路是炎症与肿瘤发生之间最重要的联系之一。NF-κB是一个转录因子超家族,在包括乳腺癌在内的多种血液系统和实体肿瘤中发挥重要作用。然而,NF-κB通路在乳腺癌患者生存中的作用研究较少。在本研究中,我们分析了经典和替代NF-κB通路的表达,并将其与乳腺癌患者的无复发生存率和总生存率相关联,同时选择了靶基因。我们使用了公共数据库Kaplan-Meier plotter(KMplot),其中包括3951例乳腺癌患者的基因表达数据和生存信息。我们发现,在雌激素受体(ER)阳性肿瘤患者中,[此处原文缺失具体基因名称]的表达与无复发生存率差相关。此外,[此处原文缺失具体基因名称]的表达与无复发生存率和总生存率差相关。相反,当根据患者的激素和淋巴结状态进行分类时,经典通路中的[此处原文缺失具体基因名称]以及替代通路中的[此处原文缺失具体基因名称]的表达与更好的无复发生存率相关。我们的研究表明,经典和替代NF-κB通路基因的表达最终对肿瘤持续存在至关重要。了解这两条通路之间的相互作用将有助于找到更好的治疗和预防靶点,以防止乳腺癌进展和复发。